Genprex, Inc. 8-K

What Happened

• On April 30, 2026, Genprex, Inc. (GNPX) announced that the Israel Patent Office (ILPO) granted a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD‑1 antibodies for cancer treatment. The company said this expands its existing intellectual property portfolio supporting REQORSA’s use with PD‑1 inhibitors and builds on patents previously granted in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe. Genprex is initially developing REQORSA in combination with approved cancer drugs to treat lung cancer; preclinical data cited by the company show complementarity with targeted drugs and immunotherapies.

Key Details

• Patent grant announced: April 30, 2026 (ILPO grant for REQORSA + PD‑1 antibodies).
• Prior patents: similar combination patents already granted in U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe.
• Development focus: REQORSA being developed initially with approved cancer drugs for lung cancer; preclinical studies reported complementary activity with targeted therapies and immunotherapies.
• Regulatory/financial caution: filing includes forward‑looking statements and risk disclosures, including risks related to clinical development, regulatory approvals, ability to obtain capital, and Genprex’s ability to regain/maintain Nasdaq listing and continue as a going concern.

Why It Matters

• For investors, the ILPO patent strengthens Genprex’s global intellectual property position for REQORSA in combination with PD‑1 antibodies, which can be important for partnering, licensing or commercialization strategies if clinical development and approvals succeed.
• The announcement does not provide new clinical or commercial results—REQUIREMENTS for safety, efficacy, manufacturing scale-up, regulatory approvals and financing remain. The company’s own filing reiterates material risks (clinical timelines, capital needs, Nasdaq compliance and going concern issues), which investors should weigh alongside the IP update.